Publicacións (107) Publicacións de José María Pego Reigosa

2024

  1. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?

    Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78

  2. SLESIS-R: an improved score for prediction of serious infection in patients with systemic lupus erythematosus based on the RELESSER prospective cohort

    Lupus Science and Medicine, Vol. 11, Núm. 1

2023

  1. Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 58

  2. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort

    Rheumatology (Oxford, England), Vol. 62, Núm. 3, pp. 1162-1169

  3. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

    Annals of the Rheumatic Diseases

  4. HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients

    Rheumatology (United Kingdom), Vol. 62, Núm. 7, pp. 2621-2630

  5. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

  6. Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)

    Seminars in Arthritis and Rheumatism, Vol. 61

2022

  1. Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology

    BMC Health Services Research, Vol. 22, Núm. 1

  2. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure

    Seminars in Arthritis and Rheumatism, Vol. 52

  3. Central Role of Semaphorin 3B in a Serum-Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis

    Arthritis and Rheumatology, Vol. 74, Núm. 6, pp. 972-983

  4. Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study

    Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224

  5. Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies

    Cells, Vol. 11, Núm. 3

  6. Myo-Spain: Spanish Registry of Patients with Idiopathic Inflammatory Myopathy. Methodology

    Reumatologia Clinica, Vol. 18, Núm. 5, pp. 253-259

  7. Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study

    The Lancet Rheumatology, Vol. 4, Núm. 6, pp. e441-e449

  8. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

  9. Recommendations for prevention of infection in systemic autoimmune rheumatic diseases

    Reumatologia Clinica, Vol. 18, Núm. 6, pp. 317-330

  10. Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients

    Archivum Immunologiae et Therapiae Experimentalis, Vol. 70, Núm. 1

  11. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 4, pp. 1529-1550

2021

  1. Calcineurin and systemic lupus erythematosus: The rationale for using calcineurin inhibitors in the treatment of lupus nephritis

    International Journal of Molecular Sciences, Vol. 22, Núm. 3, pp. 1-14